Status:
COMPLETED
Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
Lead Sponsor:
Ablynx, a Sanofi company
Conditions:
Active Rheumatoid Arthritis
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of active rheumatoid arthritis on a stable background of methotrexate (7.5-25 mg weekly).
Exclusion
- Any significant health problem other than rheumatoid arthritis
- Any clinically significant laboratory abnormalities
- Any prior use of B cell-depleting therapy
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
252 Patients enrolled
Trial Details
Trial ID
NCT00959036
Start Date
September 1 2009
End Date
January 1 2011
Last Update
January 30 2013
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site
Birmingham, Alabama, United States, 35209
2
Investigational Site
Huntsville, Alabama, United States, 35801
3
Investigational Site
Peoria, Arizona, United States, 85381
4
Investigational Site
Scottsdale, Arizona, United States, 85258